Cited by 40Smoking Behavior and CessationBipolar Disorder and TreatmentSubstance Abuse Treatment and Outcomes

A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder

Open access
Wu, Becky S., Weinberger, Andrea H., Mancuso, Enza, Wing, Victoria C., Haji-Khamneh, Bahar, Levinson, Andrea J., George, Tony P.·2012·Journal of Dual Diagnosis

Abstract

Our review of studies examining smoking cessation interventions among persons with bipolar disorders (George, Wu, & Weinberger, 2012, this issue) shows the need for safe and efficacious smoking ces...

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15504263.2012.671067

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only four published smoking cessation treatment trials in smokers with bipolar disorder were identified: one very small open pilot study with bupropion, two open pilot studies with varenicline, and two studies using varenicline either alone or in combination with CBT.

    “We identified only four published smoking cessation treatment trials in smokers with BD: one very small open pilot study with bupropion (70), two open pilot studies with varenicline (71, 72), and 2 studies using varenicline either alone (73) or in combination with CBT (74).”

    From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [72]

    The TO THE EDITOR section identifies this as a pilot study of varenicline in smokers with bipolar disorder, but explicitly describes its design as double-blind, randomized, and placebo-controlled—not open-label. The paper therefore contradicts the claim if it is being cited as one of the open pilot studies; it does not establish the citing document’s total count of published trials. (LLM, conf=0.84)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • All four identified smoking cessation treatment trials in smokers with bipolar disorder were in favor of the specific treatment.

    “All studies were in favor of the specific treatment.”

    From The detrimental effects of smoking on the course and outcome in adults with bipolar disorder—A narrative review (2023) · cites this paper as [72]

    In “TO THE EDITOR” (page not supplied), the authors report that their varenicline trial reduced smoking and that an earlier bupropion trial showed promise. The paper does not assess four treatment trials or conclude that all four favored their respective treatments; it says only one earlier study had been published at the time. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wu, B. S., Weinberger, A. H., Mancuso, E., Wing, V. C., Haji-Khamneh, B., Levinson, A. J., & George, T. P.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • Yale University (US)
Venue
Journal of Dual Diagnosis
Published
2012-04
Volume
8
Issue
2
Pages
131-132
ISSN
  • 1550-4263 (ISSN-L)
  • 1550-4271
OpenAlex
W2095330365
Cited by
40
References
8
Citations by year
2025: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 9 · 2014: 5 · 2013: 6 · 2012: 4
FWCI
5.14
Type
journal article
Language
en
Open access
Locations
  • Journal of Dual Diagnosis (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Pfizer
  • Health Canada
  • Canadian Institutes of Health Research
  • National Institute on Drug Abuse (R01DA013672, K02DA016611, K12DA000167)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
varenicline, smoking cessation, bipolar disorder, nicotine dependence, feasibility, smoking cessation interventions, dual diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review